By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a non-exclusive agreement giving it access to Evrogen's fluorescent proteins.

The deal allows Paris-based Cellectis to incorporate the proteins into its own products, expanding its portfolio of genome engineering tools.

Financial and other terms were not disclosed.

Based in Moscow, Evrogen develops technologies for molecular and cell biology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.